Resources for Researchers
The ACTG NL consists of Core Laboratory groups in immunology, pharmacology, virology and TB.
This contract provides gap-filling support services for HIV prevention drug developers including academic (investigators), for-profit and not-for-profit small and large companies, and other product innovators (henceforth identified as Sponsors) for the development of HIV non-vaccine biomedical pr
This service can be used to develop and perform a variety of analytical assays to assess the properties of drug substances and their formulations.
This service provides follow-up studies of products which already have been evaluated in a biochemical or cell-based assay and shown to possess an activity profile that warrants further development of the product as an HIV therapeutic.
This service provides evaluation of products in animal efficacy models. A product must demonstrate a potent and selective activity profile in vitro against the HIV strain used in the model prior to its acceptance as a candidate for this service.
This service can be used to provide pharmacokinetic and safety assessments of products in mice, rats, rabbits, dogs, and nonhuman primates.
This service program supports the development and manufacture, of a wide variety of pharmaceutical dosage formulations, including tablets, capsules, semi-solid preparations, injectibles, and sustained-release products. If requested, manufacturing can be done under GMP.
This service provides chemical synthesis of lead compounds for use in additional drug development studies. Compounds must previously have been successfully synthesized to be candidates for this service. Synthesis of new analogs is not supported.
The Microbicide Trials Network (MTN) is a NIAID-funded worldwide collaborative clinical trials network focused on preventing the sexual transmission of HIV. The MTN accepts concepts for new protocols, ancillary study proposals, secondary data analysis requests, and dataset requests.
This service provides evaluation of products that have already been evaluated in a biochemical or cell-based assay and shown to possess an activity profile that warrants further development as a microbicide.
The National Institutes of Health (NIH) AIDS Reagent Program provides critical research reagents and resources to the scientific community. The ARP acquires, develops, and produces state-of-the-art reagents and provides these reagents at no cost to qualified investigators throughout the world.
The Preclinical Development Support Master Contract (PDSMC) supports all phases of preclinical development, including process and product development, GMP manufacturing and clinical lot production, analytical and formulation, preclinical enabling studies and associated tasks leading to the filing
The Process Development and Analytical Support Contract (PAS) supports two key critical components: process development and analytical characterization activities.
This contract is with the International Aids Vaccine Initiative (IAVI).
Current methods for monitoring HIV-infected patients on antiretroviral therapy are expensive and technologically complex, making it difficult for use in resource-limited countries around the world.
The SVEU provides the nonhuman primates for studies to evaluate candidate SIV or HIV vaccines.